Would you offer anti-HER2 therapy to a patient found to have heterogenous HER2+ residual disease after original treatment for TNBC using the KEYNOTE-522 regimen?

Topics: Breast Cancer • Medical Oncology • Breast Cancer, Non-metastatic

Markers from surgical path showed ER0PR0 HER2 2+ and positive via FISH in 5% of total tumor population.

Answer from: Medical Oncologist at Academic Institution

This is complicated and there isn't a data driven right/wrong answer for this type of situation that I am aware of. Neoadjuvant treatment can cause shifts in biomarker results in residual tumor tissue compared to the pre-treatment specimen. KY-522 didn't do re-testing of residual tumor. I am not rou...

Comments

Medical Oncologist at Joliet Oncology Hematology Associates
Would you give this in addition to Keytruda?

Medical Oncologist at Onc San Antonio
Keytruda should be continued as adjuvant per KN522...

Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida
We have given these drugs in combination with pemb...

Related Questions